Drug intelligence / Profile preview

allerslit forte

Development stage
Phase 3
Lead developer
Allergopharma
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Sublingual
01

Overview

Allerslit forte is a high-dose sublingual immunotherapy (SLIT) product developed by Allergopharma for the treatment of grass pollen allergies. It is formulated as a sublingual solution containing grass pollen allergens. [4, 6] The therapy is intended for patients with clinically relevant grass pollen sensitivity suffering from allergic rhinitis or rhinoconjunctivitis, with or without controlled asthma. [1, 8] The mechanism of action involves perennial administration to induce immune tolerance towards grass pollen allergens, thereby reducing the allergic response and alleviating symptoms. [4, 7] Clinical studies have evaluated its efficacy and safety, showing a significant reduction in symptom and medication scores compared to placebo. [1, 14]

Brand names
allerslit forte
Other names
High-dose grass pollen allergen - AllergopharmaInfectoSlit Gräser
02

Targets

MHC II (Major histocompatibility complex class II receptor)IgE (Immunoglobulin E)

Beyond the preview

Go deeper on allerslit forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on allerslit forte.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call